RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.15
+3.25%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 4.48x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.58x
- Price / sales
- 2.71x
- Price / cash flow
- -1.91x
Enterprise value
- Enterprise value
- $435.4M
- EV / sales
- 2.50x
- EV / EBITDA
- -3.13x
- EV / EBIT
- -2.65x
- Market cap
- $472.0M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026